BeiGene: Long-term Extension Study of Zanubrutinib in Patients with B-Cell Malignancies

Purpose of this Study

We are doing this study to find the most safe and effective long-term dose of an experimental drug called zanubrutinib (the study drug) when it is given alone or in combination with other cancer drugs. We want to know how well this study drug works in people with B-cell cancers who are currently participating or previously participated in a BeiGene-sponsored study.

Who Can Participate?

Eligibility

Adults ages 18+ who:

Are actively participating or recently participated in a BeiGene-sponsored parent study
Have not been permanently discontinued from receiving the study drug in the parent study

For more information about who can join this study, please contact the study team at 919-681-6580.

What is Involved?

Description

If you choose to join this study, you will go through a screening period to find out if you are eligible. During this screening period, you will:

Have a physical exam
Have a heart scan (ECG)
Have blood draws

If you are eligible, you will begin taking the study drug. Everyone enrolled in this study will get the study drug, zanubrutinib, regardless of whether or not you received it in the previous BeiGene study in which you were enrolled. If you did not get the study drug in the previous BeiGene study in which you participated, we will do some extra tests in comparison to people who have already used the study drug. Your participation in the study may last for up to 5 years, but this will depend on how you respond to the study drug.

Study Details

Full Title

An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients with B-cell Malignancies

Principal Investigator

Danielle

Brander

Protocol Number

PRO00112490

NCT ID

NCT04170283

Phase

III

Enrollment Status

Open to Enrollment

ClinicalTrials.gov